CHONDRION
Chondrion is a SaaS based company that provides a cloud-based solution to access the retail management systems from anywhere on virtually any internet-enabled device. They also offer web-based software, to access anywhere with Wi-Fi or a smartphone signal.
CHONDRION
Industry:
Retail Technology SaaS Sales Automation Software
Address:
Clifton Park, New York, United States
Country:
United States
Website Url:
http://www.chondrion.com
Total Employee:
11+
Status:
Active
Contact:
+1 518 345 7050
Email Addresses:
[email protected]
Technology used in webpage:
Euro Amazon Amazon Ohio Region Unsplash
Similar Organizations
Acqueon
Acqueon is an innovative provider of conversational engagement software.
Advanceretail
AdvanceRetail provides retail management soloution.
Big Hammer
Big Hammer is a provider of data driven software applications.
Cloud Creations
Cloud Creations provides Salesforce consulting and development services.
Deep Forest Systems
Deep Forest Systems delivers powerful, targeted, custom-fit property management software as a service.
Elixserve
Elixserve is a provider of labor management software.
Ennoview
Ennoview is the leading provider of salon and spa management software and services.
iLandMan
iLandMan is a cloud-based land and lease management software provider.
Momentum Factor
SaaS, Compliance software , reputation management services
Official Site Inspections
http://www.chondrion.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Chondrion"
About us - Khondrion
About Khondrion. Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease. Based on proprietary science …See details»
Khondrion - Crunchbase Company Profile & Funding
Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in …See details»
Khondrion - MitoWorld
Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of …See details»
Khondrion - LinkedIn
Khondrion | 2,077 followers on LinkedIn. Bringing energy to life | We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by ...See details»
Khondrion - VentureRadar
Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a …See details»
Khondrion Company Profile - Office Locations, Competitors ... - Craft
Khondrion is a pharmaceutical company discovering and developing therapies targeting the mitochondrial disease. It is engaged in the development of therapies and biomarkers, …See details»
Khondrion receives FDA clearance of IND application for pivotal …
Nov 14, 2024 About Khondrion Khondrion is a clinical stage biopharmaceutical company developing therapies for patients with primary mitochondrial disease (PMD). The company’s …See details»
UMDF and Khondrion Announce The Mito Fund’s ... - Markets Insider
Nov 21, 2024 Like all investments made by The Mito Fund, the Khondrion consideration went through a rigorous review process by UMDF’s Venture Philanthropy Investment Committee, an …See details»
Khondrion announces publication in Brain of ... - Markets Insider
Nov 7, 2024 Sonlicromanol, Khondrion’s lead proprietary drug candidate, is a disease-modifying, potentially first-in-class, brain-penetrant redox-modulator with anti-inflammatory properties, …See details»
Chondrion
With our built-in proprietary algorithms, we automate away repetitive tasks. During implementation, we configure Chondrion to operate in the background and eliminate day-to …See details»
UMDF and Khondrion Announce The Mito Fund’s Investment in …
Khondrion. 21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical …See details»
Khondrion receives FDA clearance of IND application for pivotal …
Nov 14, 2024 Khondrion is initially focusing the development of sonlicromanol on PMD patients with the m.3243A>G variant, which is the most common genetic defect causing multi-systemic …See details»
Khondrion announces publication in Brain of integrated
Nov 7, 2024 Sonlicromanol, Khondrion’s lead proprietary drug candidate, is a disease-modifying, potentially first-in-class, brain-penetrant redox-modulator with anti-inflammatory properties, …See details»
Khondrion announces publication in Brain of integrated Phase 2b …
Nov 7, 2024 Khondrion is a clinical stage biopharmaceutical company developing therapies for patients with primary mitochondrial disease (PMD). The company’s lead asset, sonlicromanol, …See details»
UMDF and Khondrion Announce The Mito Fund’s Investment in
21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical …See details»
Khondrion announces publication in Brain of integrated Phase 2b …
Nov 7, 2024 Sonlicromanol, Khondrion’s lead proprietary drug candidate, is a disease-modifying, potentially first-in-class, brain-penetrant redox-modulator with anti-inflammatory properties, …See details»
Khondrion announces publication in Brain of integrated Phase 2b …
Nov 7, 2024 NIJMEGEN, the Netherlands – 7 November 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary …See details»
The Mito Fund Announces Investment in Khondrion to Support …
Khondrion is currently preparing to initiate a Phase III study investigating the potential of its lead proprietary drug candidate, sonlicromanol, to treat adult patients with PMD due to the …See details»
2020 - A Year in Review - Khondrion
At Khondrion I am thankful that, over the past 12 months, we have been able to make significant progress in our research developing innovative treatment options for patients with inherited …See details»